NCT03264794

the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

Evaluation of the Efficacy of Domestic Gefitinib Tablets in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Using a Multicenter, Randomized, Positive Drug Gefitinib Pharmacodynamics and Pharmacodynamics

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Jiangsu Famous Medical Technology Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

1. Gefitinib CTTQ production gefitinib and erlotinib sheet AstraZeneca imatinib sheet (trade name: Iressa ®) comparison, human pharmacokinetics and relative bioavailability of comparative studies which examine people in vivo pharmacokinetic behavior, provide the basis for clinical use. 2. Evaluation CTTQ gefitinib imatinib sheet production efficacy and safety of Chinese patients with locally advanced or metastatic non-small cell lung cancer.

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial	Gefitinib Tab （CTTQ），First medication,250mg；
DRUG	Gefitinib tablets (Yi Ruisha），First medication	Gefitinib tablets (Yi Ruisha），First medication,250mg；
DRUG	Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.	From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）

Timeline

• Start date: 2017-08-01
• Primary completion: 2021-12-01
• Completion: 2022-06-01
• First posted: 2017-08-29
• Last updated: 2017-08-29